Related Experiment Video

Updated: Jul 8, 2025

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

47.5K

Inhibition of TLR4, NF-κB, and INOS pathways mediates ameliorative effect of syringic acid in experimental ulcerative

Maryam Ghasemi-Dehnoo1,2, Hossein Amini-Khoei2, Zahra Lorigooini2

  • 1Student Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran.

Inflammopharmacology
|December 14, 2023
PubMed
Abstract

Insights

Syringic acid (SA) effectively treats ulcerative colitis (UC) in rats by reducing inflammation and oxidative stress. This study shows SA

Area of Science:

  • Pharmacology and Toxicology
  • Gastroenterology
  • Molecular Biology

Background:

  • Syringic acid (SA) exhibits various reported therapeutic properties.
  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease with limited treatment options.
  • The role of specific molecular pathways like TLR4, NF-κB, and INOS in UC pathogenesis is increasingly recognized.

Purpose of the Study:

  • To investigate the therapeutic effects of syringic acid (SA) on acetic acid-induced ulcerative colitis (UC) in a rat model.
  • To evaluate the impact of SA on key inflammatory and apoptotic pathways, including TLR4, NF-κB, and INOS.
  • To assess the antioxidant and anti-inflammatory potential of SA in the context of UC.

Main Methods:

  • Ulcerative colitis was induced in Wistar rats using intra-rectal acetic acid administration.
  • Rats were treated with varying doses of SA (10, 25, 50 mg/kg) or dexamethasone (2 mg/kg) for five consecutive days.
  • Macroscopic and histopathological damage, gene expression (inflammatory, apoptotic), antioxidant enzyme activities (SOD, CAT), TAC, NO, and MDA levels were assessed in colon tissue.

Main Results:

  • Acetic acid-induced UC significantly increased inflammatory markers, oxidative stress (NO, MDA), and apoptosis, while decreasing antioxidant capacity (TAC, SOD, CAT).
  • SA treatment dose-dependently ameliorated colon damage, reduced expression of INOS, TLR4, IL-6, IL-1β, NF-κB, Caspase-3, Caspase-8, and Bax.
  • SA significantly decreased MDA and NO levels and increased TAC and CAT activity compared to untreated UC rats.

Conclusions:

  • Syringic acid demonstrates significant therapeutic potential in managing ulcerative colitis in rats.
  • SA exerts its protective effects by attenuating the TLR4-NF-κB and NF-κB-INOS-NO signaling pathways.
  • SA effectively reduces oxidative stress, inflammation, and apoptosis in the colon, offering a promising natural therapeutic agent for UC.
Keywords:
ApoptosisInflammationStress oxidativeSyringic acidUlcerative colitis

More Related Videos

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

852
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.6K

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
129
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
142
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.0K